Jazz launches Sunosi

After its May 2019 FDA approval, Jazz Pharmaceuticals is hitting the ground running with its launch of Sunosi, used to treat narcolepsy, but also for patients with obstructive sleep apnea (OSA).

Jazz estimates 12 million people in the U.S. have been diagnosed with OSA, but it believes many others have gone undiagnosed.

The campaign, called “A Different Kind of Tired,” is centered on research that found 36% of sleep apnea patients missed activities or events, avoided social situations or gave up activities because of excessive sleepiness.

Click here to read the entire article.